Plasma tetranectin and ovarian neoplasms.

Abstract

Plasma tetranectin was measured in 67 controls, 121 patients with a benign or malignant ovarian tumor, and 24 patients with another benign gynecologic disease to evaluate the predictive value of plasma tetranectin. A significant reduction of plasma tetranectin was found in every malignant tumor type except for mucinous tumors. Further a significant correlation was found between stage of tumors and plasma tetranectin. Depending on the cutoff level the sensitivity for stage 1 cancer ranged from 52 to 71%. In stage 1 + 2 the sensitivity ranged from 58 to 75% and for advanced cancer (stage 3 + 4) from 80 to 95%. The corresponding specificities ranged from 97 to 84%. Plasma tetranectin may be a useful tool for detecting early stages of ovarian cancer.

• Authors: C K Høgdall, E V Høgdall, U Hørding, S Daugaard, I Clemmensen, B Nørgaard-Pedersen, K Toftager-Larsen
• Journal: Gynecologic oncology (Gynecol Oncol) Vol. 43 Issue 2 Pg. 103-7 (Nov 1991) ISSN: 0090-8258 [Print] United States
• PMID: 1743549 (Publication Type: Journal Article)

Chemical References

• Blood Proteins
• Lectins, C-Type
• tetranectin

Topics

• Adult
• Aged
• Aged, 80 and over
• Blood Proteins (analysis)
• Enzyme-Linked Immunosorbent Assay
• Female
• Humans
• Lectins, C-Type
• Middle Aged
• Neoplasm Staging
• Ovarian Neoplasms (blood, pathology)
• Reference Values
• Sensitivity and Specificity